Frontlight ResearchEarly access
CompletedPhase 2
A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcers
Key facts
- Who runs it
- Aurealis Oy
- Where
- Germany, Italy, and Poland9 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 100 people enrolled
- Started
- 21 Jul 2023
- Ended
- 9 Oct 2025
- Type of study
- Interventional
- Record updated
- 9 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 44 criteriaShow less
Who can take part
- Male or female patients aged 18 years and above, depending on the Investigator’s assessment of physical and psychological wellbeing of the patient to comply with study procedures and follow-up
- Females of childbearing potential must agree to use a highly effective contraceptive measure (methods that can achieve a failure rate of less than 1% per year when used consistently and correctly) , throughout the study. / Male patients who are biologically capable of having children must agree to apply at least two methods of contraception including male barrier protection throughout the study
- Patients who understand and are willing to comply with study procedures and give written informed consent prior to enrolment in the study or initiation of study procedures
- Patients with diabetes mellitus (DM) of type 1 or 2 having a glycosylated haemoglobin (HbA1c) of ≤ 11.0% OR 97.0 mmol/mol OR 14.9 mmol/l at randomization (results up to 3 months prior to signing ICF accepted) undergoing therapy for glycaemic control using available diabetes drugs including insulin
- Patients with at least one DFU that fulfils all of the following criteria: •Non-healing target ulcer defined as ≤ 20.0 % reduction in area in response to SoC during the 2-weeks run-in period, • Duration: ≥4 weeks and ≤12 months at screening visit 1, • Located either in the plantar or on the dorsum of foot, or at or below the ankle, • Ulcer is accessible for administration of IMP and can be completely covered by the primary and secondary dressings, • Full-thickness, not involving bone or joints (i.e., University of Texas classification Grade 1A, 1C, 2A, 2C)(5) • No clinical signs of active wound infection defined by IDSA/IWGDF criteria(6) or clinical evidence osteomyelitis at randomization (V1), • Area of the target ulcer between 1.0-10.0 cm2 after debridement at randomization (V1), • Ulcer and periwound tissue suitable for application of semipermeable film dressings (i.e., no contraindications and sufficient periwound space to hold the dressing)
- Patients with more than one ulcer will be included if ulcers are separated by a minimum of 2.0 cm healthy tissue. The largest ulcer fulfilling inclusion criteria will be selected for the investigational treatment
- Patients with either an ankle brachial index (ABI) ≥ 0.7 OR a toe-brachial index (TBI) ≥ 0.5, AND a toe systolic pressure of at least 50.0 mmHg (or ankle systolic pressure of at least 70.0 mmHg if toe-pressure is not measured) on the foot with the target ulcer
- Revascularized patients with an ulcer fulfilling the inclusion criteria can be included 3.0 months after the procedure
- Patients with an assessment of the baseline level of neuropathy in the lower limb where the target ulcer is located
- Patients must be willing to wear off-loading footwear, while ambulating, for the period requested by the Investigator
- A woman of childbearing potential (WOCBP) must have a negative serum pregnancy test at the time of screening after sign the informed consent and a negative pregnancy dip-stick test at baseline (before starting treatment)
Who cannot take part
- Current or previous (within 2 weeks prior to start of run-in period) treatment with another investigational drug and/or medical device or participation in another clinical study
- Target ulcers requiring urgent vascular surgical interventions
- Prior radiation therapy (within 6 weeks prior to first IMP (AUP1602-C or placebo) dosing) of any part of the foot/leg bearing the target ulcer under study or total body irradiation
- Patients receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) therapy
- Positive for hepatitis B or C virus (HBV, HCV), or human immunodeficiency virus (HIV) (serology test results up to 3 months prior signing ICF accepted)
- Patients with confirmed active infection with SARS-CoV-2 and related disease (COVID-19) at Baseline (V1) prior to first administration of trial medication
- Planned major surgery during the run-in, treatment and post-treatment efficacy and safety follow-up period of the study
- Known abuse of alcohol, drugs, or medical products. Tobacco use will be allowed
- Previous treatment with AUP1602-C
- Myocardial infarction diagnosed within 1 month prior to start of run-in period
- Current or previous (within 1 week prior to first IMP (AUP1602-C or placebo) dosing) treatment with active wound care agents (e.g., local/topical antibiotics OR antibacterials such as silver, iodine, chlorhexidine) OR systemic antibiotics for any indication
- Pregnant or lactating woman at the time of signing the informed consent and prior to first IMP (AUP1602-C or placebo) dosing
- Current or previous (within 2 weeks prior to first IMP (AUP1602-C or placebo dosing) use of corticosteroids and immunosuppressants. Treatment with immunosuppressive agents with known therapeutic effects longer than 2 weeks may be considered as exclusion and should be consulted with Medical Monitor/Sponsor
- Target ulcer with known or suspected active infection, which requires antimicrobials. Any antibiotic therapy must be completed or discontinued within 1 week prior to first IMP (AUP1602-C or placebo) dosing
- Target ulcer other than non-healing DFU fulfilling inclusion criteria (e.g., including, but not limited to, pressure ulcers, burn wounds)
- Sickle-cell diseases, Reynaud’s, or other peripheral vascular disease including venous leg ulcers or any vasculitic ulcer irrespective of the cause will be excluded
- Patients with other reasons for wound healing disturbances: e.g., bleeding disorders, vitamin K deficiency, hypocalcaemia, major immune deficiencies
- Active malignant disease of any kind except for basal cell carcinoma (of the skin) not co-located with the target ulcer. A patient, who has had a malignant disease in the past, completed treatment and is currently disease-free and not on active treatment for at least 3 months, may be considered for study entry. Cancer therapies with known therapeutic effects longer than 3 months may be considered as exclusion and should be consulted with Medical Monitor/Sponsor
- Any diagnosed unstable psychological or physical condition including major organ failure that could interfere with compliance
- Known hypersensitivity to any of the components of AUP1602-C or placebo
- Ulcer of University of Texas Grade ≥3, with deep abscess, sinus track, necrosis or gangrene that cannot be removed by debridement
- Serum creatinine level of >3.0 times the upper limit of normal (ULN)
- Haemoglobin of less than 8.5 g/dL
- Liver transaminase & total bilirubin levels greater than 3 times ULN
- Current or previous (within 30 days prior to start of run-in period) treatment of target ulcer with a treatment that could interfere with wound healing/IMP such as biological agents, growth factors, skin equivalents/substitutes (e.g., Regranex®, Apligraf®, or Dermagraft®), keratinocytes, platelet-rich-plasma, collagen products, blood products, placental products, oxygen therapy, topical steroids
- White Blood Cells (WBC) < 3.0 x 109 cells/L; > 12.0 x 109 cells/L
- Albumin < 2.5 g/dL (or total protein < 4.0 g/dl)
- Active or unstable Charcot deformity of the study foot (i.e., foot is erythematous, warm, oedematous, and is actively remodelling)
- The patient has any other factor/reason which may, in the opinion of the Investigator, compromise participation and/or follow-up in the study
- Close affiliation with the Investigator (e.g., a close relative, financially dependent on the investigational site) or patient who is an employee of the Sponsor’s company
- Patients who are institutionalized because of legal or regulatory order
- Target ulcers with excessive exudation requiring more than one dressing change within 24-hrs
- Target ulcers with clinically significant periwound skin maceration
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate local and systemic safety and tolerability of the recommended Phase 2 Dose (RP2D) (2.5 x 108 CFU/cm2 ulcer size) and selected treatment schedules of AUP1602-C and of the placebo control arm, in patients with DFU fulfilling inclusion criteria.
Read full original descriptionShow less
To evaluate the proportion of patients achieving total wound closure with the 2 dosing frequencies of AUP1602-C and placebo treatment.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 9 October 2025